Evonik Health Care
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.9 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life, today and tomorrow.
Evonik Vancouver Laboratories, formerly known as Transferra Nanosciences Inc. or Northern Lipids, has been a market CDMO leader for lipid nanoparticle (LNP)-/liposome-based formulations for almost 30 years. We have an unparalleled track record in early stage development, scale-up and production of lipid-based formulations for gene-based therapies and other advanced nanomedicines. As a specialist CDMO for lipid nanoparticles (LNPs) with a broad base of pharmaceutical and biotech clients across the world, we have accumulated extensive expertise across virtually all classes of pharmaceuticals. Hundreds of LNP-based formulations have been developed by us to-date, including oncology, vaccines, nucleic acids (mRNA, DNA, siRNA), ligand-targeted formulations and imaging contrast agents. We are also leading the CDMO market for LNPs to address emerging areas of market need including drug combinations, immunotherapies and individualized treatments. In addition, we design and manufacture LIPEX™ line of extruders, which are designed to enable small-scale to commercial scale manufacturing of specific liposomal drug products.
Biotechnology, Contract Research & Scientific Services, Scientific Supplies
- cGMP/GLP Compliance
- Contract Manufacturing
- Drug Delivery
- Gene Therapy
- Immune Therapy
- Infectious Diseases
- mRNA
- Nanomedicine
- Oncology
- Pre-Clinical Services
- Therapeutics
- Vaccines
Contract Research & Scientific Services , Scientific Supplies
As a CDMO for LNP-based drug delivery, we bring together a range of market-leading drug discovery and pre-clinical services that can reduce risk and streamline your path to commercial launch. We have extensive expertise in early stage formulation development, including the choice of lipid excipients and appropriate buffer systems, preparation and characterization of nanoparticle prototypes for feasibility testing. Other common R&D-stage CDMO services for LNPs include the identification of the most scalable manufacturing process, the development of analytical methods, and the co-ordination of stability studies to establish storage conditions. Preclinical program activities include scale-up and manufacturing for GLP toxicology, analytical method development for long term stability studies, test article preparation for IND enabling toxicology studies, and the development of drug product specifications.
Member Profile
Biotechnology, Contract Research & Scientific Services, Scientific Supplies
Evonik Health Care
Bronze Sponsor

- Website healthcare.evonik.com/en/pharmaceuticals/parenteral-drug-delivery/cdmo-services/drug-deliver
- Email jane.meyer@evonik.com
- Address
8855 Northbrook
Burnaby, BC
V5J 5J1 - Leadership Contact
Jane M. Meyer, M.S., M.A. Global Head of Parenteral Services
April 26, 2022
Doping for Bacteria: Evonik Presents New Technology to Boost Efficiency in Wastewater Treatment
March 22, 2022
Evonik Invests in New ROHACELL® Production Facility
February 23, 2022
Evonik Strengthens World-scale Methionine Production Hub in the U.S.
November 23, 2021
Virtual Open House at our Sites in Vancouver and Birmingham
No current content.